Le Lézard
Classified in: Health, Business
Subjects: AWD, LGB, DEI

Nobelpharma America Earns 2023 Great Place to Work® Certificationtm in U.S.; Focus on Collaboration, Trust, Results


BETHESDA, Md., April 4, 2023 /PRNewswire/ -- Nobelpharma America, specialists in developing treatments and medical devices for rare diseases, announced it has received certification by Great Places to Work® for its values-based company culture and the quality of the workplace environment. This marks the first time Nobelpharma America has won the prestigious recognition, which is based on what current employees say about their experiences working there.

Great Place to Work® is a globally recognized and research-based verification of workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. According to Great Place to Work research, job seekers are 4.5 times more likely to find a great boss at a certified great workplace. Additionally, employees at certified workplaces are 93 percent more likely to look forward to coming to work and are twice as likely to be paid fairly and have a fair chance at promotion.

"Being formally recognized as one of the best places in the U.S. to work is extremely gratifying," said Head of Human Resources, Administration and Compliance at Nobelpharma America, Susan Ways. "It shows that great things happen when the top priority in managing a workplace is employee empowerment, satisfaction and professional development. Nobelpharma America is a thriving, results-oriented company where trust and collaboration are the keys to success. Great Place to Work® Certificationtm confirms our strong commitment to these important values."

Nobelpharma America offers a variety of benefits, resources and programs to support employees in being their best in aspects of their lives ? at work, at home, and everywhere in between. Nobelpharma recently launched its first pharmaceutical product into the U.S. rare diseases marketplace. Nobelpharma America was established in the U.S. in 2019, employs approximately 39 employees in the U.S. and is a wholly-owned subsidiary of Nobelpharma Co., Ltd., based in Tokyo.

Nobelpharma America is a pharmaceutical and medical device company committed to developing treatments and medical devices for diseases that often go overlooked because of the small number of patients affected.

For more information on Nobelpharma, America, including career opportunities, please visit https://www.nobelpharma-us.com/.

About Great Place to Work® Certificationtm
Great Place to Work® Certificationtm is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience ? specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified.

About Great Place to Work®
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: Trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For Alltm.

Learn more at greatplacetowork.com, LinkedInTwitterFacebook and Instagram.

About Nobelpharma America 
Nobelpharma America, LLC (NPA) is focused on the commercialization of pharmaceuticals and medical devices that expand treatment options for people with rare diseases. In 2019, NPA became the first wholly owned global subsidiary of Nobelpharma Co., Ltd., which is based in Tokyo. The company, which is named after Alfred Nobel, remains committed to honoring his innovative and scientific legacy by developing treatments for diseases that often go overlooked because of the small number of individuals affected. For more information visit nobelpharma-us.com


Media Contact Information:



Nobelpharma America, LLC                                       

Method Health Communications,  LLC


Name: Susan Ways,                                                     

Name: Sheila Burke


Head of Human Resources,                                         

Telephone: 484-667-6330


Administration and Compliance                                    

Email: [email protected]


Nobelpharma America



Telephone: 301-244-5951



[email protected]


SOURCE Nobelpharma America


These press releases may also interest you

at 05:40
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer. Jurgen, who has served as Global Commercial Director since June 2023,...

at 05:12
"According to the latest BCC Research study, the demand for Global Skin Allergy Testing Market is expected to grow from $560 million in 2023 and is projected to reach $771.5 million...

at 03:30
Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the publication of a...

at 03:30
Commit Biologics ("Commit"), a pioneer in the...

at 03:29
Hugel, a global total medical aesthetics company, announced its 1Q24 consolidated financial results on the 9th, reporting revenue of KRW 74.3 billion, operating profit of KRW 24 billion, and net income of KRW...

at 03:00
"LASTE" (LArge Stroke Therapy Evaluation), a prospective, randomized, controlled trial co-led by Professor Vincent Costalat (neuroradiologist, Montpellier, France) and Dr. Caroline Arquizan (vascular neurologist,...



News published on and distributed by: